細胞名稱

人胰腺癌細胞MIA PaCa-2

貨物編碼

BFN60803981

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研           1類

培養(yǎng)體系

DMEM高糖培養(yǎng)基（Hyclone）+10%胎牛血清（Gibco）+2.5%馬血清+1%雙抗（Hyclone）

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人胰腺癌細胞MIA PaCa-2細胞表達人集落刺激因子CFS-I和血漿酶原激活劑。該細胞引種自ATCC CRL-1420

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Doubling time: 26 hours (PubMed=25984343); 25.7 +- 4.3 hours (PubMed=27067801); 40 hours, 18 hours, in serum-free medium (PubMed=23386380); ~40 hours (ATCC); ~30-40 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis by 2D-DE/MS.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Caution: Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814.

Misspelling: MiaPaCa-1; In PubMed=15770730.

STR信息

AMEL:X,X；CSF1PO:10,10；D12S391:19,19；D13S317:12,13；D16S539:10,13；D18S51:12,12；D19S433:15,15；D21S11:29,31.2；D2S1338:25,25；D2S441:14,14；D3S1358:16,16；D5S818:12,13；D6S1043:12,12；D7S820:12,13；D8S1179:16,16；FGA:22,22；Penta D:12,16；Penta E:13,18；TH01:9,10；TPOX:9

參考文獻

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31037374; DOI=10.1007/s00216-019-01814-1

Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B.

Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry.

Anal. Bioanal. Chem. 411:6319-6328(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)